75 related articles for article (PubMed ID: 33432065)
1. A Genome-Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early-Stage Breast Cancer Patients.
Sanchez-Spitman AB; Böhringer S; Dezentjé VO; Gelderblom H; Swen JJ; Guchelaar HJ
Clin Pharmacol Ther; 2024 Jul; 116(1):155-164. PubMed ID: 38501904
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction.
Baneshi MR; Warner P; Anderson N; Edwards J; Cooke TG; Bartlett JM
Br J Cancer; 2010 May; 102(10):1503-10. PubMed ID: 20461093
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.
Wang T; Zhou Y; Cao G
Eur J Clin Pharmacol; 2021 Aug; 77(8):1095-1111. PubMed ID: 33515076
[TBL] [Abstract][Full Text] [Related]
4. Clinical
Mulder TAM; de With M; Del Re M; Danesi R; Mathijssen RHJ; van Schaik RHN
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33673305
[TBL] [Abstract][Full Text] [Related]
5. Distribution of
Abudukeremu M; Ayoufu A; Tuerhong A; Paizula X; Ou JH
Open Life Sci; 2024; 19(1):20220728. PubMed ID: 38681733
[TBL] [Abstract][Full Text] [Related]
6.
Tareen MU; Riaz S; Malik SS; Zahid S; Khursheed A; Tariq F; Abbas F; Malik MN; Anis RA; Anees M; Murtaza I; Sultan A
Exp Biol Med (Maywood); 2023 Sep; 248(17):1507-1517. PubMed ID: 37688505
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of indole-modified tamoxifen relatives as potent anticancer agents.
Ertugrul B; Aytatli A; Karatas OF; Saracoglu N
RSC Med Chem; 2023 Jul; 14(7):1362-1376. PubMed ID: 37484572
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer.
Souwer ETD; Sanchez-Spitman A; Moes DJAR; Gelderblom H; Swen JJ; Portielje JEA; Guchelaar HJ; van Gelder T
Breast Cancer Res Treat; 2023 Jun; 199(3):471-478. PubMed ID: 37067610
[TBL] [Abstract][Full Text] [Related]
9. The Role of microRNAs in Multidrug Resistance of Glioblastoma.
Mahinfar P; Mansoori B; Rostamzadeh D; Baradaran B; Cho WC; Mansoori B
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804989
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.
Nthontho KC; Ndlovu AK; Sharma K; Kasvosve I; Hertz DL; Paganotti GM
Pharmgenomics Pers Med; 2022; 15():613-652. PubMed ID: 35761855
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen and oxidative stress: an overlooked connection.
Ahmed NS; Samec M; Liskova A; Kubatka P; Saso L
Discov Oncol; 2021 May; 12(1):17. PubMed ID: 35201439
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results using a kit to measure tamoxifen and metabolites concentrations in capillary blood samples from women with breast cancer.
Rehnmark S; Shabo I; Randahl H; Wengström Y; Rydberg P; Hedayati E
Sci Rep; 2022 Jan; 12(1):1643. PubMed ID: 35102224
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.
Sanchez-Spitman AB; Swen JJ; Dezentjé VO; Moes DJAR; Gelderblom H; Guchelaar HJ
Sci Rep; 2021 Jan; 11(1):415. PubMed ID: 33432065
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
Schroth W; Antoniadou L; Fritz P; Schwab M; Muerdter T; Zanger UM; Simon W; Eichelbaum M; Brauch H
J Clin Oncol; 2007 Nov; 25(33):5187-93. PubMed ID: 18024866
[TBL] [Abstract][Full Text] [Related]
15. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
Powers JL; Buys SS; Fletcher D; Melis R; Johnson-Davis KL; Lyon E; Malmberg EM; McMillin GA
J Clin Pharmacol; 2016 Dec; 56(12):1570-1581. PubMed ID: 27198207
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.
Sim S; Lövrot J; Lindh JD; Bergh J; Xie H
Pharmacogenomics; 2018 Aug; 19(13):1027-1037. PubMed ID: 30022682
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
